Nilogrin (Nicergoline)

Nicergoline, the active ingredient in Nilogrin, is an ergot alkaloid presented as an unknown/unknown for oral use. It is used to improve cerebral blood flow in adults with cerebrovascular insufficiency. GNH USA supplies Nilogrin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicergoline acts on the cerebrovascular system to enhance cerebral perfusion and is employed in several recognised conditions. - Cerebral vascular insufficiency: improves blood flow and reduces related symptoms. - Age‑related cognitive decline: supports mental function in older adults. - Vascular dementia: may help stabilise cognition in dementia of vascular origin.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness, especially on standing. - Headache: transient cranial pain. - Gastro‑intestinal discomfort: abdominal pain or dyspepsia. - Hypotension: occasional drop in blood pressure. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Bleeding complications: due to platelet inhibition. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm. - Vasospasm: rare constriction of blood vessels.

When prescribing Nilogrin, consider the following precautions. - Renal impairment: monitor kidney function and adjust use if needed. - Hepatic disease: assess liver enzymes before initiation. - Bleeding disorders: avoid or use with caution because of antiplatelet effects. - Pregnancy and lactation: limit use to situations where benefits outweigh potential risks. - Concomitant ergot drugs: avoid combined use to prevent additive vasospasm. - Store at below 25°C: keep in the original pack, protect from moisture.

Nilogrin may interact with several drug classes; awareness helps prevent adverse outcomes. Major Interactions (Avoid): - Other ergot derivatives: increased risk of vasospasm. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise nicergoline plasma levels. - Anticoagulants (e.g., warfarin): heightened bleeding tendency. Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - SSRIs/SNRIs: potential for increased bleeding risk.